These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Defining intractability: comparisons among published definitions. Berg AT; Kelly MM Epilepsia; 2006 Feb; 47(2):431-6. PubMed ID: 16499772 [TBL] [Abstract][Full Text] [Related]
4. Is pseudo-intractability in population of patients with epilepsy still alive in the 21st century? Audit of 100 seizure-free patients, referred with the diagnosis of pharmacoresistant epilepsy. Bajacek M; Hovorka J; Nezadal T; Nemcova I; Herman E Neuro Endocrinol Lett; 2010; 31(6):818-22. PubMed ID: 21196921 [TBL] [Abstract][Full Text] [Related]
5. Early seizure frequency and aetiology predict long-term medical outcome in childhood-onset epilepsy. Sillanpää M; Schmidt D Brain; 2009 Apr; 132(Pt 4):989-98. PubMed ID: 19153149 [TBL] [Abstract][Full Text] [Related]
6. When to start drug treatment for childhood epilepsy: the clinical-epidemiological evidence. Arts WF; Geerts AT Eur J Paediatr Neurol; 2009 Mar; 13(2):93-101. PubMed ID: 18567515 [TBL] [Abstract][Full Text] [Related]
7. Pharmacologically intractable epilepsy in children: diagnosis and preoperative evaluation. Go C; Snead OC Neurosurg Focus; 2008 Sep; 25(3):E2. PubMed ID: 18759621 [TBL] [Abstract][Full Text] [Related]
9. A graded system to categorize drug-resistant epilepsy. Gomez-Alonso J; Gil-Nagel A Epilepsia; 2010 Nov; 51(11):2360-1. PubMed ID: 20977473 [No Abstract] [Full Text] [Related]
10. [Drug-resistant epilepsy]. Nakken KO; Taubøll E Tidsskr Nor Laegeforen; 2009 Oct; 129(19):1986-9. PubMed ID: 19823202 [TBL] [Abstract][Full Text] [Related]
11. The definition and prediction of intractable epilepsy in children. Farrell K; Wirrell E; Whiting S Adv Neurol; 2006; 97():435-42. PubMed ID: 16383154 [No Abstract] [Full Text] [Related]
12. Epilepsy in patients with angelman syndrome caused by deletion of the chromosome 15q11-13. Valente KD; Koiffmann CP; Fridman C; Varella M; Kok F; Andrade JQ; Grossmann RM; Marques-Dias MJ Arch Neurol; 2006 Jan; 63(1):122-8. PubMed ID: 16401744 [TBL] [Abstract][Full Text] [Related]
13. Identification of pharmacoresistant epilepsy. Berg AT Neurol Clin; 2009 Nov; 27(4):1003-1013. PubMed ID: 19853220 [TBL] [Abstract][Full Text] [Related]
14. Monogenic epilepsies in humans: molecular mechanisms and relevance for the study of intractable epilepsy. Cossette P; Rouleau GA Adv Neurol; 2006; 97():381-8. PubMed ID: 16383149 [No Abstract] [Full Text] [Related]
15. Definition of drug-resistant epilepsy: is it evidence based? Wiebe S Epilepsia; 2013 May; 54 Suppl 2():9-12. PubMed ID: 23646963 [TBL] [Abstract][Full Text] [Related]
16. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP Epilepsy Behav; 2007 Mar; 10(2):296-303. PubMed ID: 17317325 [TBL] [Abstract][Full Text] [Related]
17. Likelihood of seizure remission in an adult population with refractory epilepsy. Callaghan BC; Anand K; Hesdorffer D; Hauser WA; French JA Ann Neurol; 2007 Oct; 62(4):382-9. PubMed ID: 17880009 [TBL] [Abstract][Full Text] [Related]
18. Intractable epilepsy in adults. Leppik IE Adv Exp Med Biol; 2002; 497():1-7. PubMed ID: 11993725 [TBL] [Abstract][Full Text] [Related]
20. Seizure relapse and development of drug resistance following long-term seizure remission. Schiller Y Arch Neurol; 2009 Oct; 66(10):1233-9. PubMed ID: 19822778 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]